Remove 2016 Remove Hospital Remove Individual Remove Medical
article thumbnail

Predictors of exposure to high-priority drug-drug interactions among non-elderly adults in Quebec, Canada [Prescribing and pharmacotherapeutics]

Annals of Family Medicine

Drug reimbursement claims were used to identify periods of overlapping exposure to 2 or more prescription drugs between April 1, 2015 and March 31, 2016. Results: Our cohort included 63,834 individuals aged 19-64 (mean age 44.9 Study design and Analysis: Retrospective cohort study using provincial administrative health databases.

Community 130
article thumbnail

Risking It All For a New Business Model at Family Physicians of St. Joe

Family Physicians of St. Joseph

The practice steadily grew through the 80’s and 90’s, and Dr. Eggebrecht joined in 1993, at a time when family doctors still rounded in the hospital and delivered babies. The individuals who make up the practice impact the community in a variety of ways. From the time of its inception until October 2017, Family Physicians of St.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Our guests explain how we can incorporate race-conscious medicine in clinical settings, medical education, and biomedical/epidemiological research to responsibly recognize and address the harms of racial inequality. These factors include a high-protein diet, muscle mass, creatinine generation, and certain medications.

Clinic 52
article thumbnail

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

FDA Law

Lenz, Principal Medical Device Regulation Expert & Sophia R. Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Gaulkin & Jeffrey N.

article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

FDA Law

The CDS Guidance interprets the “medical software” carve-out of the 21st Century Cures Act (2016) as it pertains to Clinical Decision Support (CDS) software functions. The CDS Guidance interprets the Cures Act’s definition of “medical software” that is excluded from the statutory “device” definition, as it relates to CDS software.

Clinic 52
article thumbnail

Exposure to high-priority drug-drug interactions among non-elderly adults in Quebec: a cohort study [Prescribing and pharmacotherapeutics]

Annals of Family Medicine

DDI exposures were considered incident if the individual was not exposed to a DDI in the year preceding cohort entry. 2) Hazard ratio for an adverse event (emergency room visit, hospitalization, or death). or 7,498/63,834 individuals in the cohort were exposed to at least one high-priority DDI over 12 months in 2015-2016.

article thumbnail

CDC Proposes Updating Practice Guideline for Prescribing Opioids, Warning Against Continued Misapplication

FDA Law

We blogged on the final 2016 guideline here on March 17, 2016). As explained more fully below, CDC concedes that states, insurers, pharmacies and pharmacy benefit managers have implemented laws, regulations and policies that have misapplied the 2016 guideline. 2016 Guideline. Purpose of the Proposed Guideline.